Results 161 to 170 of about 3,904 (178)

Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial

Lancet, The, 2022
Edward Loftus, Julian Panes, Remo Panaccione   +2 more
exaly  

Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease: A GETAID multicentre cohort study

Alimentary Pharmacology and Therapeutics, 2023
Lucine Vuitton, Mathurin Fumery, David Laharie   +2 more
exaly  

Risankizumab improves PsA

Nature Reviews Rheumatology, 2022
openaire   +2 more sources

A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab

Clinical, Cosmetic and Investigational Dermatology, 2023
Angelo Ruggiero, Matteo Megna, Luca Potestio   +2 more
exaly  

Risankizumab for Crohn's disease

The Lancet, 2022
openaire   +2 more sources

Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial

Lancet, The, 2019
KRISTIAN Reich, Diamant Thaçi, Melinda Gooderham   +2 more
exaly  

Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the SustaIMM phase 2/3 trial

Journal of Dermatology, 2019
Mamitaro Ohtsuki, Atsuyuki Igarashi, Susumu Kitamura   +2 more
exaly  

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

Lancet, The, 2018
Peter Foley, Howard Sofen, Mamitaro Ohtsuki   +2 more
exaly  

Risankizumab

2020
Erica B. Lee, Deeti J. Pithadia, Kelly A. Reynolds, Jashin J. Wu   +3 more
openaire   +1 more source

Risankizumab/tacrolimus

Reactions Weekly, 2021
openaire   +1 more source